<?xml version="1.0" encoding="UTF-8"?>
<p id="par0120">CXCL8 (also referred at as IL-8) is another chemokine considered as a potential prognostic bio-marker for ARDS clinical course [
 <xref rid="bib0195" ref-type="bibr">39</xref>]. Indeed, CXCL8 levels were found to be elevated both in plasma [
 <xref rid="bib0200" ref-type="bibr">[40]</xref>, 
 <xref rid="bib0205" ref-type="bibr">[41]</xref>, 
 <xref rid="bib0210" ref-type="bibr">[42]</xref>, 
 <xref rid="bib0215" ref-type="bibr">[43]</xref>] and in the broncho-alveolar lavage fluid [
 <xref rid="bib0220" ref-type="bibr">[44]</xref>, 
 <xref rid="bib0225" ref-type="bibr">[45]</xref>, 
 <xref rid="bib0230" ref-type="bibr">[46]</xref>] of patients with ARDS. A direct role of CXCL8 in the progression of ARDS was proven in rabbit with acid-induced ARDS lead to a 10-fold increase in CXCL8 levels in the alveolar fluids. Of note, pre-treatment with an anti-CXCL8 antibody prevented the development of the typical acute lung injury [
 <xref rid="bib0235" ref-type="bibr">47</xref>].
</p>
